CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

With Omicron still the prevailing strain of COVID-19 around the world, the new shot is now Moderna's "lead candidate for a fall 2022 booster," he added. Some expert groups, including the Joint ...

James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

Moderna has filed complaints in the US and ... and stake a claim to the potentially lucrative opportunity for booster shots targeting new variants like Omicron as COVID-19 becomes endemic.

According to the US' CDC, the ongoing clade II 2022 mpox outbreak has been responsible for over 100,000 infections in 122 countries to date worldwide.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The Centers for Disease Control and Prevention might soon limit its guidance for who should receive a coronavirus booster ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...